Established in May 2017, AnLing Biomed (Suzhou) Co., Ltd. is a professional contract research organization (CRO) for drug development initiated by the core team of Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The company focuses on preclinical research services for pharmaceuticals, including customized design of early drug development plan, pharmacodynamics screening, pharmacodynamics evaluation, metabolism, safety evaluation, etc. The company renders services to customers mainly including drug R&D companies with valuable services on preclinical pharmacodynamics, pharmacokinetics, and safety evaluation. With NMPA GLP certification, it has successfully rendered high-quality services to more than 200 biopharmaceutical companies and R&D organizations from over 20 provinces and cities in China, as well as in Europe, the United States, Japan and other Southeast Asian countries. The core members of the team have nearly 20 years of industry experience, and the consultants graduated from the United States, Europe and Japan, including PhDs, masters and two nominees under the "Hundred Talents Program" of Chinese Academy of Sciences.

Hunan Experimental Dog Breeding and Research Base

Guangxi Non-human Primate Breeding and Research Base

AnLing Biomed (Shenzhen) Co., Ltd. was established in April 2020 with the support of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and the government of Pingshan District, Shenzhen, as a preclinical research and transformation service platform for drugs and medical devices that meets GLP standards in China and other countries. Located at Building 2, Biomedicine Innovations Industrial Park, Pingshan District, Shenzhen, the facility covers an area of nearly 10,000 square meters to carry out studies of toxicology, metabolism and pharmacodynamics. Its R&D services produce data up to the standards of NMPA, EMA OECD and US FDA applications. This allows the company to provide customers in South China, nationwide, and worldwide with professional, high-level research and development services for drugs and medical devices in an all-round way. Experimental animals are available including rat, mouse, hamster, rabbit, guinea pig, dog, mini pig, monkey and sheep. AnLing Biomed (Shenzhen) has obtained important qualifications such as Laboratory Animal Use Certification, full accreditation from AAALAC International, BSL-2, and NMPA GLP certification of 8 items. The team has been engaged in drug safety evaluation research for more than 20 years with its core members from Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The consultant team consists of academicians of Chinese Academy of Engineering, academicians of Chinese Academy of Sciences, FDA medical officers, GLP inspectors, AstraZeneca's former senior pathologists, and senior safety pharmacologists, etc.

ZSHK (Hong Kong) is a drug safety testing center jointly established by ZSHK Laboratories Limited and Hong Kong Science and Technology Park. It is the first facility in Hong Kong that meets GLP standards and can provide toxicology, genotoxicity, toxicokinetics, safety pharmacology, reproductive toxicology, pharmacokinetics (ADME) and other preclinical services.